Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06089863

Rehabilitation Program on Genetic and Degenerative Ataxia

Cerebellar ataxia is a pathology linked to the lesion of the cerebellum or the afferent and/or efferent cerebellar pathways. The aetiology can be an acquired cerebral lesion, following a chemical poisoning or a genetic degenerative lesion (for example : Friedreich's ataxia, spinocerebellar ataxias, etc.). As reported by the latest estimate available, genetic degenerative cerebellar ataxias affect approximately 6,000 patients in France (Orpha.net). Symptoms suffered by ataxic patients are : problems and gait disorders along with difficulties in coordination resulting in ataxia, uncoordinated movements.

These symptoms cause a decrease in the quality of life on patients with spinocerebellar ataxia. The symptoms improvement linked to the cerebellar syndrome is based on rehabilitation that can be supplemented by use of technical aids. Current scientific knowledge confirms that intensive rehabilitation by physiotherapy and occupational therapy in patients with degenerative ataxias improves cerebellar symptoms. Nevertheless, the choice rehabilitation technique stay at the appreciation of the therapist.

From the observation, the investigators have designed an intensive multidisciplinary rehabilitation program, called PAMPERO, with partner patients member of two genetic degenerative ataxia patient organisations. This 5-weeks program has been used in clinic during 3 years on 28 patients. It appears to be the only one in France.

The preliminary results show a positive effect on ataxia symptom. Nevertheless, the duration of the benefice over time and the effect on the quality of life stay unknown.

However, the quality of life is mainly affected by the participation restriction due to the risk of falling. The most frequent complaint from partner patient is the diminution of the social interaction resulting of the incapacity to move without risk.

The present protocol aimed at evaluating the Rehabilitation Program in collaboration with partner patient on the symptom intensity, activity and quality of life on genetic and degenerative ataxia.

This PAMPERO program's effect will be assessed by comparing the difference of Intensity of symptom measured by to Scale for the Assessment and Rating of Ataxia (SARA) at inclusion and 3 months after the end of rehabilitation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Ataxia Brain Diseases Central Nervous System Diseases Cerebellar Ataxia Cerebellar Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Degenerative Disease Dyskinesias Genetic Disease Genetic Diseases, Inborn Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service de Rééducation Fonctionnelle (S.S.R.) Val Rosay, Saint-Didier-au-Mont-d'Or, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years
  • Patients with genetic and degenerative cerebellar ataxia
  • Diagnostic of cerebellar ataxia confirmed by anatomic MRI
  • Affiliated to a social insurgence regime or similar
  • Patients who have given their free, informed and express consent
  • Walking patients (who can walk unsupervised on flat ground with the help of proper technique : categories greater than 4 on the New Functional Ambulation Classification scale)

Non inclusion Criteria:

  • Patients who have already benefited from a hospitalization of more than 3 weeks for rehabilitation during the last 12 months
  • Patients participating simultaneously in another research whose objective would be the evaluation of a therapy, medicinal or not, likely to improve neurological or functional recovery
  • Pregnants, parturient or breastfeeding
  • Patients deprived of their liberty by a judicial or administrative decision
  • Psychiatric care patients
  • Patients admitted to Patients admitted to a health or social establishment for purposes other than research for purposes other than research
  • Major patients protected by the Law

Treatment and study plan

PAMPERO program

Other

This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow :

  • 5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object
  • 5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority
  • 1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick
  • 2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture
  • 2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation

Primary outcomes

  1. Scale for the Assessment and Rating of Ataxia (SARA)

    Time frame: Inclusion ; 3 months after the end of rehabilitation

    Intensity of symptom measured by to Scale for the Assessment and Rating of Ataxia (SARA). Scores are from 0 to 42. An higher score is associated with a worse outcome.

Secondary outcomes

  1. Scale for the Assessment and Rating of Ataxia (SARA)

    Time frame: Inclusion ; Immediately or 1 week after the end of rehabilitation ; 6 months after the end of rehabilitation

    Intensity of symptom measured by to Scale for the Assessment and Rating of Ataxia (SARA). Scores are from 0 to 42. An higher score is associated with a worse outcome.

  2. Score of the Mini-BESTest scale

    Time frame: Inclusion ; Immediately or 1 week after the end of rehabilitation ; 3 months after the end of rehabilitation ; 6 months after the end of rehabilitation

    Measure of the balance evaluate by Mini-BESTest scale (Mini-Balance Evaluation Systems Test). Scores are from 0 to 28. An higher score is associated with a better outcome.

  3. Eyes open postural surface

    Time frame: 5 weeks

    Measure of the balance evaluate by the Eyes open postural surface

  4. Displacement length of the center of mass as a function of time eyes open

    Time frame: 5 weeks

    Measure of the balance evaluated by the displacement length of the center of mass as a function of time eyes open

  5. Scale of Short Falls Efficacy Scale International (Short FES-I)

    Time frame: Inclusion ; Immediately or 1 week after the end of rehabilitation ; 3 months after the end of rehabilitation ; 6 months after the end of rehabilitation

    Fear of fall evaluated by to Scale of Short Falls Efficacy Scale International (Short FES-I). Scores are from 7 to 28. An higher score is associated with a worse outcome.

  6. Number of weekly steps

    Time frame: Inclusion ; Immediately or 1 week after the end of rehabilitation ; 3 months after the end of rehabilitation ; 6 months after the end of rehabilitation

    Number of steps during one week continuously measured by actimeter ActiGraph wGT3X-BT with EUROCOC (European Certificate of Conformity)

  7. Time of weekly sedentary activity

    Time frame: Inclusion ; Immediately or 1 week after the end of rehabilitation ; 3 months after the end of rehabilitation ; 6 months after the end of rehabilitation

    Time in minutes/day of sedentary activity during one week continuously measured by actimeter ActiGraph wGT3X-BT with EUROCOC

  8. Light, moderate and vigorous weekly activity

    Time frame: Inclusion ; Immediately or 1 week after the end of rehabilitation ; 3 months after the end of rehabilitation ; 6 months after the end of rehabilitation

    Light, moderate and vigorous activity during one week continuously measured by actimeter ActiGraph wGT3X-BT with EUROCOC

  9. Short Form Health Survey (SF-36)

    Time frame: Inclusion ; Immediately or 1 week after the end of rehabilitation ; 3 months after the end of rehabilitation ; 6 months after the end of rehabilitation

    Measure of the quality of life evaluate by Short Form Health Survey (SF-36). Scores are from 0 to 100. An higher score is associated with a better outcome.

  10. Number of falls during the study

    Time frame: 4 weeks ; up to 3 months ; up to 6 months

    Risk of falling evaluated by the number of falls during and outside the rehabilitation normalized on 4 weeks

  11. Number of patients who completed the entire PAMPERO program

    Time frame: 5 weeks

    Number of patients who completed the entire PAMPERO program (5 weeks)

  12. Number of patients who stopped PAMPERO program

    Time frame: 5 weeks

    Number of patients who stopped PAMPERO program

  13. Time to occurrence of PAMPERO program stops

    Time frame: 5 weeks

    Time to occurrence of PAMPERO program stops

  14. Reasons of PAMPERO program stops

    Time frame: 5 weeks

    Reasons of PAMPERO program stops

Study contacts

Contact information is provided by the study sponsor or research team.

Christelle MAROLHO

CONTACT

[email protected]

04 72 11 57 68 ext. +33

Lucas PIGNON

CONTACT

[email protected]

04 78 86 50 58 ext. +33

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Evaluation of the Effect of PAMPERO Rehabilitation Program in Collaboration With Patient Partner on the Symptom Intensity, Activity, and Quality of Life on Genetic and Degenerative Ataxia

Acronym: RAPP

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Oct 18, 2023
Registry last updated
Jan 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.